Consecutive subjects with MPM undergoing pre-operative staging with <sup>18</sup>F-FDG PET/CT who underwent a same day integrated <sup>18</sup>F-FDG PET/MRI were prospectively studied.
The semi-quantitative analysis of <sup>18</sup>F-FDG PET/CT has an important role in MPM therapy response assessment and has a predictive role in distinguishing responders and non-responders.
<sup>18</sup>F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.
FDG PET-derived parameters effectively discriminated patients with a poor prognosis and may be helpful in the selection of MPM patients for salvage HTT.
Histologically confirmed MPM patients (N=82) who were treated with three cycles of cisplatin and pemetrexed, or carboplatin and pemetrexed, were included. mRECIST and integrated 18F-FDG-PET/CT were used to evaluate MPM tumor response to chemotherapy.